- Global Pharma News & Resources

Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma

*         ICARIA (Isatuximab in Combination with pomalidomide And low-dose dexamethasone veRsus pomalidomide and low dose dexamethasone in patients with refractory or relapsed And refractory Multiple Myeloma), study evaluated the benefit of isatuximab in combination with standard of care in prolonging progression free survival as compared to standard of care in patients with relapsed/refractory multiple myeloma

*         Multiple myeloma is the second most common haematological cancer1

*         First randomised Phase 3 trial to evaluate the benefit of adding a monoclonal antibody to pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma

ICARIA, the pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma, met the primary endpoint of prolonging progression free survival in patients treated with isatuximab in combination with pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone alone (standard of care).



Results will be submitted to an upcoming medical meeting and are anticipated to form the basis of regulatory submissions planned for later this year.


Commenting on the ICARIA results, Professor Kwee Yong, UK ICARIA Trial Investigator and Professor of Haematology at University College London Hospital explains: “There is a continuing need for new therapeutic options for multiple myeloma in patients who have either relapsed or are no longer responding to their current treatment. The ICARIA study confirms that the investigational agent, isatuximab, in combination with the current standard of care, pomalidomide, improves outcomes for these patients and I’m excited about how these data demonstrate the ability of this investigational compound to extend disease free life in patients living with relapsed/refractory multiple myeloma.”


Multiple myeloma is the second most common haematologic cancer, with approximately more than 5,500 people diagnosed each year in the UK at any one time, it is estimated that 17,500 people are living with this condition. Multiple myeloma remains incurable in the vast majority of patients, resulting in significant disease burden.

Dr Marc Moodley, Medical Director for Sanofi Genzyme said: “There is an unmet need in the management of relapsed/refractory multiple myeloma and the ICARIA data represents a significant milestone for Sanofi Genzyme and our oncology portfolio. The isatuximab development programme continues to progress and we are committed to bringing this investigational compound forward as a potential new therapeutic option for patients as soon as possible.”